• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Therapix and CURE to Collaborate With Israeli Medical Center

July 11, 2017


This morning, CURE Pharmaceutical (OTC:CURR) and Therapix Biosciences (NASDAQ:TRPX) announced that they have signed a memorandum of understanding to enter into a research collaboration with Israel's Assuta Medical Centers. 


About the Collaboration 


The goal of the collaboration is to advance, research, develop and commercialize potential cannabinoid therapeutic products. The companies intend to pool professional, scientific and financial resources to advance these goals. CURE and Therapix will contribute their expertise in regards to the development of pharmaceutical products and Assuta will provide research and facilities to support early stage R&D. 


Management Commentary


CURE Pharmaceutical's CEO, Robert Davidson


"As CURE focuses on targeting unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options, we are continuously looking to help bring new therapeutic cannabinoid-based products to market and further efforts toward the creation of personalized medicine. " Our new collaboration with Therapix and Assuta, two leading companies in Israel, a Country that is at the forefront of cannabinoid-based research in the world, is the perfect place to start the development of these products."


Therapix Biosciences' Chairman, Dr. Ascher Shmulewitz


"CURE is the ideal partner for us to enter this promising and cutting-edge personalized cannabinoid-based therapeutics; this deal has all the signs of a fruitful venture."


Assuta Medical Centers' CEO, Professor Ari Shamiss


"Assuta is happy to enter into the MOU with CURE and Therapix, and I am confident that the parties' cooperation will be a successful one, with many other projects to follow. This new collaboration is yet another step Assuta is taking in the innovation world, and one of many steps to be taken by Assuta in the field of biopharma."


Market Reaction


Shares of Therapix trading in Tel Aviv are up more than 5% in late trading there. In U.S. pre-market trading, shares of Therapix are up nearly 7%. CURE Pharmaceuticals finished yesterday's session at $7.60, up 2.60% on the day. We'll be watching to see how shares of both companies kick off today's U.S. trading session. 



To learn more about Therapix, check out their marijuana stock profile in The Daily Marijuana Observer's cannabinoid biotech stock database. Remember, shares of Therapix can be traded commission free using the Robinhood App


Also, be sure to subscribe to The Daily Marijuana Observer's free Israeli cannabis and cannabinoid biotech email newsletters.


If you haven't already, connect with The Daily Marijuana Observer on Facebook, Twitter and Instagram.





Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.​

Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.